
Ep. 393 - China trends; Roche, Merck KGaA deals; Arrowhead & tau
Episode 393
Roche’s $15 billion biobucks deal with Hansoh for preclinical ADCs is the latest in a string of China licensing deals carrying unusually large upfronts for early-stage assets. On the latest BioCentury This Week podcast, BioCentury’s analysts assess trends to watch ahead of Shanghai Life Sciences Week, including how new rules have curtailed China’s IIT pathway and a proposed export-control regime that could complicate cell and gene therapy and siRNA deals. The analysts also discuss Merck KGaA’s $1.3 billion takeout of Silence, Arrowhead’s brain-shuttle tau data and the dose dilemma facing tau-lowering therapies, and whether a preclinical biotech like Isomorphic Labs can justify a $40-50 billion valuation. View full story: https://www.biocentury.com/article/661224 #ChinaBiotech #siRNA #BiotechMA #DrugDiscovery #DrugDevelopment 0:00 Introduction 1:13 China Trends 9:00 Roche-Hansoh Deal 13:11 Merck KGaA Buys Silence 15:38 Arrowhead's Brain Shuttle 23:40 Isomorphic Labs Valuation To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text
Publisher
BioCentury This Week
Published
October 20, 2026
Duration
30 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
BioCentury
BioCentury This Week
@biocenturythisweek
#chinatrends #merckkgaadeals #arrowhead #lifesciences
